Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

Research output: Contribution to journalComment/debate

43 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)11-12
Number of pages2
JournalNature Reviews Clinical Oncology
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cell- and Tissue-Based Therapy
Administrative Personnel
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology

Cite this

Tisagenlecleucel - The first approved CAR-T-cell therapy : Implications for payers and policy makers. / Prasad, Vinay.

In: Nature Reviews Clinical Oncology, Vol. 15, No. 1, 01.01.2018, p. 11-12.

Research output: Contribution to journalComment/debate

@article{e9af20e84c2e437aa17c6c03806394ce,
title = "Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers",
author = "Vinay Prasad",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/nrclinonc.2017.156",
language = "English (US)",
volume = "15",
pages = "11--12",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Tisagenlecleucel - The first approved CAR-T-cell therapy

T2 - Implications for payers and policy makers

AU - Prasad, Vinay

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85038247975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038247975&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2017.156

DO - 10.1038/nrclinonc.2017.156

M3 - Comment/debate

C2 - 28975930

AN - SCOPUS:85038247975

VL - 15

SP - 11

EP - 12

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -